The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Improving approaches to treatment and clinical trial design
Xavier Leleu, MD, MSc, PhD , Poitiers University Hospital, Poitiers, France, shares some insights into how approaches to clinical trials and treatment in multiple myeloma should be changed, drawing focus on the importance of novel immunotherapeutic agents. Prof. Leleu highlights the controversies surrounding this topic and shares some opinions on how treatment and clinical trial design may be improved. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
